Authors
Jeong Woo Lee, Hae Do Jung, Joo Yong Lee, Hoon Choi, Tae Hyoung Kim
Published in
Investigative and clinical urology. Volume 67. Issue 6. Pages 571-578.
Abstract
To investigate the clinical efficacy and safety of 6-month long-term prophylaxis with Uro-Vaxom® in women with recurrent urinary tract infection (UTIs).
A total of 1,819 women aged ≥19 years with recurrent UTIs were enrolled from 70 institutions in Korea between November 2021 and May 2023. The primary endpoint was the number of UTI episodes during the 6-month Uro-Vaxom® prophylaxis period compared with the 6 months before initiation of prophylaxis. Secondary endpoints included time until the appearance of the first UTI, duration of antibiotic use, patient satisfaction assessed by the Patient Global Impression of Change (PGIC), and adverse events (AEs).
The mean number of UTI episodes in the 1,066 evaluable patients significantly decreased during the Uro-Vaxom® prophylaxis period compared with the preceding 6 months (0.32 vs. 2.14, p<0.0001). The mean time until the appearance of the first UTI was significantly prolonged during prophylaxis (68.89 days vs. 33.97 days, p<0.0001). The mean duration of antibiotic use decreased from 3.00 days before prophylaxis to 1.22 days during Uro-Vaxom® use (p<0.0001). In the PGIC survey for changes in patient satisfaction, the proportion of patients who answered "very much improved" or "much improved" was 42.7% at 3 months of Uro-Vaxom® use and 54.8% at 6 months. A total of 110 AEs were registered. Fourteen AEs in ten participants were assessed as serious but not unexpected or logically related to Uro-Vaxom®.
Six-month Uro-Vaxom® prophylaxis demonstrated significant preventive efficacy and an acceptable safety profile in women with recurrent UTIs.
PMID:
42990040
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0